Novo Nordisk said its highly anticipated Phase 3 readout showed that CagriSema only managed 22.7% weight loss at 68 weeks, failing to hit the 25% benchmark the company, investors and analysts were seeking.
The result ...
↧
Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned
↧